An Open Label Pilot Study Assessing the Impact of Chromium Picolinate Supplementation on Appetite and Cravings in Overweight Individuals

Inclusion Criteria:

* Males/Females age 35-70 years old, inclusive
* Self-reported BMI between 25-31 kg/m²
* In good general health at the time of screening (Investigator discretion, applied against the objective screening data and the exclusion criteria below - i.e., confirmation that no significant, unlisted comorbidity or acute condition is present that would confound assessment of appetite/craving outcomes or compliance), defined as medically stable for at least the last 6 months.
* Self-reported weight stable, defined as body weight has not fluctuated significantly over the last 3 months. "Significantly" is defined as a change of more than 3% to 5% of total body weight, or a shift over 5 lbs (Pagidipati 2021) Moderate food cravings, defined as a score 25-54 on the Food Cravings Questionnaire -Reduced (FCQ-15)
* Able to read and understand English.
* Able to read, understand, and provide informed consent.
* Able to use a personal smartphone device and download the Chloe app by People Science.
* Able to receive shipment of the product and supplies at an address within the United States.
* Able to complete study assessments over the course of up to 15 weeks.

Exclusion Criteria:

* Participants actively engaged in weight loss programs or actively dieting.
* Participants taking any supplements (i.e. fat burners, etc.) specifically for weight loss/management (including appetite control)
* Participants taking any cinnamon, berberine, or chromium containing supplements.
* Do not have a personal smartphone, internet access, or unwilling to download Chloe.
* Current or prior use of a GLP-1 within the last 2 weeks
* Concomitant Therapies:

Participants receiving any investigational therapies or treatments within 30 days prior to consent.

* Other Illnesses or Conditions: Participants who have the following comorbidities or gastrointestinal illnesses are excluded:
* Currently diagnosed with Alcohol Use Disorder and/or Substance Use Disorder
* Currently diagnosed with an Eating Disorder
* Currently pregnant, planning to become pregnant in the next 3 months, or breastfeeding
* Any underlying medical conditions or comorbidities that may confound the assessment of digestive symptoms or the evaluation of the study outcomes.
* Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes.
* Known hypersensitivity or previous allergic reaction to chromium containing products.
* Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator.